We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-1.86%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$14.7B
AUM Growth
-$908M
Cap. Flow
-$379M
Cap. Flow %
-2.57%
Top 10 Hldgs %
84.38%
Holding
107
New
11
Increased
15
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$63.8M
2
ADPT icon
Adaptive Biotechnologies
ADPT
+$51.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$26M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$22.4M
5
HRTX icon
Heron Therapeutics
HRTX
+$20M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$184M
2
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$97.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$69.5M
4
GHDX
Genomic Health, Inc.
GHDX
+$55.6M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$38.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.63%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUTL
76
Autolus Therapeutics
AUTL
$381M
$2.52M 0.02%
156,773
– –
YMAB
77
DELISTED
Y-mAbs Therapeutics
YMAB
$2.35M 0.02%
102,800
– –
CYCN icon
78
Cyclerion Therapeutics
CYCN
$15M
$2.32M 0.02%
+10,129
New +$2.87M
FSTX
79
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$2.26M 0.02%
153,286
– –
NXTC icon
80
NextCure
NXTC
$20.5M
$2.25M 0.02%
+12,500
New +$2.6M
CTMX icon
81
CytomX Therapeutics
CTMX
$694M
$2.18M 0.01%
194,377
– –
MTEM
82
DELISTED
Molecular Templates, Inc.
MTEM
$2.12M 0.01%
16,949
– –
NTLA icon
83
Intellia Therapeutics
NTLA
$1.52B
$2.1M 0.01%
128,538
– –
IDYA icon
84
IDEAYA Biosciences
IDYA
$3.46B
$1.99M 0.01%
+200,000
New +$2.18M
CCXI
85
DELISTED
ChemoCentryx, Inc.
CCXI
$1.93M 0.01%
207,029
– –
CNST
86
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$1.64M 0.01%
133,333
– –
GLMD icon
87
Galmed Pharmaceuticals
GLMD
$4.42M
$1.58M 0.01%
1,198
– –
RNTX
88
Rein Therapeutics
RNTX
$65.9M
$1.47M 0.01%
+102,000
New +$2.68M
DOVA
89
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$1.4M 0.01%
+99,405
New +$945K
FOMX
90
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.19M 0.01%
498,189
– –
SRRA
91
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.12M 0.01%
50,000
– –
ADMS
92
DELISTED
Adamas Pharmaceuticals
ADMS
$1.07M 0.01%
172,630
– –
INFI
93
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.04M 0.01%
580,400
– –
RCUS icon
94
Arcus Biosciences
RCUS
$3.32B
$966K 0.01%
121,534
– –
FLGT icon
95
Fulgent Genetics
FLGT
$560M
$835K 0.01%
125,000
– –
AFMD
96
DELISTED
Affimed
AFMD
$574K ﹤0.01%
20,000
– –
AQST icon
97
Aquestive Therapeutics
AQST
$464M
$418K ﹤0.01%
99,600
– –
VIRX
98
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$405K ﹤0.01%
15,905
– –
AIXC
99
AIxCrypto Holdings Inc
AIXC
$13.4M
$300K ﹤0.01%
22
– –
DVAX
100
DELISTED
Dynavax Technologies
DVAX
$299K ﹤0.01%
75,000
– –
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2019 Portfolio in Review

As of Q2 2019, Baker Bros. Advisors held 107 positions worth $14.7B, down 5.8% from $15.6B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors's Q2 2019 filing shows 11 new, 15 increased, 16 reduced and 4 closed positions. Its largest new stake was Atreca, Inc. Class A Common Stock: 3,532,760 shares worth $66.6M. The largest sale was Incyte, an estimated $184M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q2 2019 buy was Atreca, Inc. Class A Common Stock: 3,532,760 shares worth $66.6M.
  • Baker Bros. Advisors added most to Neurocrine Biosciences in Q2 2019, an estimated $26M increase.
  • Baker Bros. Advisors's biggest Q2 2019 reduction was Incyte, cutting an estimated $184M.
  • Baker Bros. Advisors fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $97.2M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $14.7B portfolio in Q2 2019.
  • Baker Bros. Advisors opened 11 new positions and closed 4 in Q2 2019.
  • Baker Bros. Advisors's portfolio value fell 5.8% quarter-over-quarter to $14.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.